Skip to main content
FDA Updates, Adverse Events, CDK4/6 Inhibitors
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
Read More
FDA Updates, Multiple Myeloma
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
Read More
FDA Updates, Multiple Myeloma
Abecma First CAR T-Cell Therapy Approved for Multiple Myeloma
Read More
HOPA Abstracts, Gynecologic Cancers, Screening
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
Abstract #CT11
Read More
HOPA Abstracts, Chemotherapy, COVID-19
Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic
Abstract #PM07
Read More
HOPA Abstracts
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
Abstract #PM06
Read More
HOPA Abstracts, Chemotherapy
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
Abstract #PM05
Read More
HOPA Abstracts, Infusion Issues
The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices
Abstract #PM04
Read More
HOPA Abstracts, Chemotherapy
Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses
Abstract #PM03
Read More
HOPA Abstracts, Adverse Events
Impact of Drug Repository Program in a Rural Oncology Clinic
Abstract #PM02
Read More
Page 91 of 197
Results 901 - 910 of 1963